Top Markets
Coin of the day
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Kedudukan dalam Saham #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Harga Saham
$0.0001
Disegerakkan terakhir: 2026-07-02
Modal Pasaran
$2.20K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan Cotinga Pharmaceuticals Inc. (COTQF)

Kategori

Bilangan saham terbitan bagi Cotinga Pharmaceuticals Inc. (COTQF)
Bilangan saham terbitan setakat August 2026: 0
Menurut laporan kewangan terkini dan harga saham Cotinga Pharmaceuticals Inc., bilangan saham terbitan semasa ialah 0. Pada akhir August 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Cotinga Pharmaceuticals Inc. (COTQF) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M -
US
62.19M -
NL
- -
CH
0.00 -
BE
- -
KR